Tumor Imaging in Cancer Drug Development

Organization: Hanson Wade

Venue: Sheraton Boston Hotel

Location: Boston, Massachusetts, United States

Event Date/Time: Apr 30, 2013 / 9:00 am - (EST) End Date/Time: May 02, 2013 / 4:00 pm - (EST)
Report as Spam



Tumor Imaging in Cancer Drug Development is the only meeting in the USA that will allow you to address the key challenges that you face in tumor imaging. 

The conference is designed so you can hear from drug developers and imaging experts specially chosen from Sanofi, Eisai, Genentech, Abbvie, Daiichi Sankyo, Pfizer, Millennium Pharmaceuticals and other leading cancer-focussed organizations. Learn from them. Ask them questions. Discuss your priorities.With the dedicated networking opportunities built into the agenda, you’ll be sure to add these experts to your contact list for future communication and thought-collaboration. 

Attend and access new information, cutting edge ideas, inspiring and perception-changing case studies.  You’ll leave with a dozen new ideas you can implementto improve your imaging capabilities and make a bottom line difference to your organization’s ability to deliver quality results from tumor imaging.  

Top 10 reasons to attend
  • Use imaging to better predict disease progression and tailor cancer therapies to match
  • Discover how to overcome the chemical challenges in tracer development to enhance the reliability of your imaging agent
  • Enhance your analysis of imaging data to better infer pharmacodynamic activity
  • Explore novel tumor imaging modalitites to enhance the predictive value of traditional platforms
  • Unravel the complex biology of tumors through novel imaging technology and mathematical models
  • Translate novel agents for cancer imaging into humans to better predict the presence of a target on the tumor
  • Explore the best strategies available to outsource your imaging capabilities and streamline cancer drug development
  • Identify the potential of hybrid imaging to visualize different biological aspects of metastatic lesions
  • Assess the technical aspects of preclinical and clinical molecular imaging in decision making
  • Develop strategies to manipulate the tumor microenvironment and translate these strategies into improved cancer detection


39 Dalton St
United States


Hanson Wade